Does Cymbalta cause acne? (+5 factors)
By
Ivan Kahwa
Author bio
Mr Ivan Kahwa is a chemist and phytopharmaceutical scientist with expertise in chemistry, pharmacology, phytochemistry, and Nanobiotechnology. He writes and reviews content on these topics.
Mr Ivan Kahwa’s Highlights:
Guest Researcher at the University of Leipzig, Senior Research Fellow/Scientist, and Lecturer at the Department of Pharmacy, Faculty of Medicine, Mbarara University of Science and Technology.
Professional Experience:
Mr Ivan joined PHARMBIOTRAC as a research fellow/scientist during his master of science tenure. He contributed to the development of most of the phytopharmaceutical products in the project. Furthermore, he participated in carrying out the pharmacological activities of the developed products in laboratory animals such as mice and rats in order to develop proper doses hence leading to pre-clinical studies.
With the above relevant research experience, Ivan started to work with the University of Leipzig on collaborative projects with Mbarara University to develop the chemistry of Ugandan Medicinal plants and their pharmacological activities. This was coupled with several consultative positions by different German NGOs. Mr. Kahwa is also a supporting in the teaching and learning at the Departments of Pharmacy and Pharmaceutical Sciences, Faculty of Medicine, Mbarara University of Science and Technology.
With the increase in antimicrobial resistance globally, Ivan retooled his thinking towards developing new naturally derived antibiotic regimens from Ugandan propolis with the assistance of nanotechnology to improve their delivery to microbial cells. Kahwa has also published over 28 articles in peer-reviewed journals and he is currently reviewing for many journals.
Education:
2023-2027: PhD in Pharmaceutical Sciences (ongoing) with a focus on Pharmaceutical Microbiology and Nanobiology at Mbarara University of Science and Technology.
2022: 2Msc. in Pharmacognosy and Natural Medicine Science at Mbarara University of Science and Technology.
2018: Bachelor of Science (Chemistry) at Mbarara University of Science and Technology.
Publications:
▪ Iqbal, S., Jabeen, F., Kahwa, I., & Omara, T. 2023. Suberosin Alleviates Thiazolidinedione-Induced Cardiomyopathy in Diabetic Rats by Inhibiting Ferroptosis via Modulation of ACSL4-LPCAT3 and PI3K-AKT Signaling Pathways. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-023-09804-7
▪ Gupta, A. K., Yadav, R., Sharma, S., Sawale, J., & Kahwa, I. 2023. Anti-ageing Activity and Antioxidant Activity of Methanol Extracts of Leaves and Flowers of Salvia officinalis and Rosmarinus officinalis. Journal of Young Pharmacists, 15(3), 448–455. https://doi.org/10.5530/jyp.2023.15.60
▪ Tolo, C.U., Kahwa, I., Nuwagira, U., Weisheit, A. and Ikiriza, H., 2023. Medicinal plants used in treatment of various diseases in the Rwenzori Region, Western Uganda. Ethnobotany Research and Applications, 25, pp.1-16.
https://ethnobotanyjournal.org/index.php/era/article/view/4683
▪ Kahwa, I., Ajayi, C.O., Yadav, R., Chauhan, N.S., Shah, K., Abdelgadir, A.A., Shegena, E.A., Daniel, S., Omara, T., Asiimwe, J.B. and Ikiriza, H., 2023. Pharmacognostic and phytochemical studies as an invaluable approach for correct identification of medicinal plants: The case of Artemisia vulgaris L. substituted for Artemisia annua L. in Western Uganda. TMR Integr Med, 7, p.e23004.
https://doi.org/10.53388/TMRIM202307004
▪ Nalimu, F., Oloro, J., Kahwa, I. and Ogwang, P.E., 2021. Review on the phytochemistry and toxicological profiles of Aloe vera and Aloe ferox. Future Journal of Pharmaceutical Sciences, 7, pp.1-21.
https://doi.org/10.1186/s43094-021-00296-2
▪ Elamin, O.H.S., Ali, M.A., Elgezuli, I.A.A., Bashir, M.A. and Kahwa, I., 2021. Diagnosis of pre-and post-treatment of echinococcus granulosus with counter current immune electrophoresis and bacterial co-agglutination. Journal of Microbiology and Infectious Diseases, 11(02), pp.88-94.
https://doi.org/10.5799/jmid.951600
Published book Chapter
▪ Kahwa, I., Ayesiga, I., Nakalema, S., Alinaiswe, R., Mbabazi, R. and Iqbal, S., 2023. Natural products in the management of onchocerciasis. In Natural Products in Vector-Borne Disease Management (pp. 63-80). Academic Press. Book Chapter.
https://doi.org/10.1016/B978-0-323-91942-5.00012-4
Submitted manuscripts Under Review:
▪ Comparison of the Wound Healing Activity of the Leaf and Leaf Ash Extracts of Vernonia amygdalina in Rats. Journal name: Clinical Phytoscience
▪ Ethnobotanical Survey of Medicinal plants used in the management of cancer in Uganda. Journal name: Journal of Herbal Medicine
▪ Ethnobotanical survey and phytochemical screening of medicinal plants used in treatment of epilepsy by PROMETRA-Uganda Traditional Health Practitioners in Mpigi District, Uganda. Journal name: Journal of Ethnopharmacology
Submitted book chapters under review
1.Book title: Algae as a Natural Solution for Water-Food-Energy Nexus, Section 4: Microalgae and cyanobacteria for food applications, Chapter 4.6: Safety, toxicological and allergenic aspects of using algae for food. Authors: Christine Kyarimpa, Tom Omute, Caroline K. Nakiguli, Alice V. Khanakwa4, Christopher Angiro, Ivan Kahwa, Fortunate Ahumuza, Timothy Omara*. Publisher: Springer Nature Singapore Pte Ltd. 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore.
2.Book title: Nutraceuticals Inspiring the Contemporary Therapy for Lifestyle Diseases. Chapter: Nutraceutical applications of Seaweeds and their Phytocompounds in Nutrition and Treatment of Diseases. Authors: Ivan Kahwa, Timothy Omara , Innocent Ayesiga , Gael Noel Neh Neba Ambe , Zehbanaz Javidbhai Panwala , Rachel Mbabazi , Shabnoor Iqbal , Christine Kyarimpa , Christine Betty Nagawa , Kamal Shah ,Nagendra Singh Chauhan* Publisher: CRC Press
You can view my works on the following professional sites:
Research Gate: https://www.researchgate.net/profile/Ivan-Kahwa
Google Scholar: https://scholar.google.com/citations?user=tOwrvqoAAAAJ&hl=en
ORCID: https://orcid.org/0000-0002-6440-3437
Linkedin: https://de.linkedin.com/in/ivan-kahwa-865450159
In this article, we will discuss whether Cymbalta causes acne. We will also explore research studies suggesting the link between the use of Cymbalta and acne occurrence, as well as the factors that may increase the risk of acne while taking this medication. Additionally, we will discuss alternatives to Cymbalta if it causes severe acne.
Does Cymbalta cause acne?
Yes, Cymbalta may cause acne. However, it is not a common side effect associated with the use of this medication. It may cause also skin rash, lesions, and pruritus. Skin-related side effects of Cymbalta are rare but they may occur in some individuals.
Cymbalta is an antidepressant medication that commonly works by increasing the concentration of certain neurotransmitters in the brain, that are involved in the regulation of mood and behavior. It is indicated in the management of various health conditions such as anxiety, depression, and fibromyalgia (1).
The side effects associated with the use of this medication are generally mild to moderate, with the most common side effects including dizziness, nausea, tiredness, sleep disturbance, and gastrointestinal discomfort (1).
What does research suggest?
There is limited research available on the occurrence of acne after using Cymbalta. However, a research study reported a case where a 60 mg dose of Cymbalta was used to treat obsessive-compulsive disorder in a patient.
After 2 to 3 weeks of treatment, the patient reported severe acne. In response to this, the healthcare provider adjusted the dose of Cymbalta to half, which resulted in the reduction of acne (2).
In another study, it was observed that the administration of Cymbalta to a patient with pre-existing depression led to the development of acne and facial rash. Despite these side effects, the decision was made to continue the use of the medication, and supplementary treatment for acne was initiated with antibiotics (3).
What factors can increase the risk of Cymbalta-induced acne?
Several factors may increase the risk of acne while taking Cymbalta. These factors may include:
Individual Sensitivity: Individual sensitivity to Cymbalta may increase the risk of various side effects, including skin rash and acne. Individuals with sensitive skin are prone to developing acne after using Cymbalta.
Concurrent Medications: Some medications are commonly associated with causing acne as a common side effect. The concurrent use of these medications with Cymbalta may increase the risk of skin breakouts and acne. Examples of such medications include corticosteroids, isoniazid, cyclosporine, and carbamazepine.
Underlying Medical Conditions: Individuals with underlying conditions such as stress and polycystic ovary syndrome might be more likely to experience this side effect of Cymbalta.
Unhealthy Diet: An unhealthy diet, including excessive consumption of junk food and high glycemic meals, may increase the risk of acne while taking Cymbalta in some individuals.
History of Acne: Individuals with a history of acne and genetic factors increase the likelihood of developing acne while using Cymbalta.
It is important to note that while the risk of acne with the use of Cymbalta is generally lower, in the presence of these factors, the risk increases. It’s crucial for individuals taking Cymbalta to be aware of these factors and discuss any concerns with their healthcare provider.
What to do if Cymbalta causes acne?
If you experience a skin reaction or acne after using Cymbalta, it is important to inform your healthcare provider. Your healthcare provider will analyze your symptoms and identify any risk factors that may be responsible for your condition.
In the presence of risk factors such as an unhealthy diet and underlying medical conditions, your healthcare provider may first address these. However, if Cymbalta is determined to be the sole cause of your symptoms, your healthcare provider may recommend dosage adjustment, or in some cases, discontinuation of the medication.
Dosage adjustment typically aims to reduce the incidence of side effects of Cymbalta, including acne. If you continue to experience these side effects, your healthcare provider may recommend discontinuing the medication (2).
However, it is crucial to note that Cymbalta should not be discontinued without the guidance and direction of your healthcare provider, as sudden withdrawal of this medication may lead to unwanted side effects that could worsen your condition.
What are the alternatives to Cymbalta if it causes acne?
If you’re experiencing severe and persistent acne after using Cymbalta, your healthcare provider may recommend alternative medications that are less likely to cause acne-related skin issues compared to Cymbalta. These medications may include (4,5):
- paroxetine
- fluoxetine
- venlafaxine
- doxepin
- mirtazapine
However, it’s essential to note that while these medications might have a lower incidence of acne, they may have other side effects that should be monitored to ensure the effectiveness and safety of treatment.
The choice of a suitable medication should be based on individual medical conditions and overall health status. However, if the benefits of Cymbalta outweigh the risks, it is advised to continue the medication.
In my opinion, Cymbalta may cause acne however, the side effects of Cymbalta usually subside after a few weeks of treatment, and your mental health is more important than the skin-related side effects of Cymbalta, including acne.
Was this helpful?
References
1.-
Dhaliwal JS, Spurling BC, Molla M. Duloxetine. [Updated 2023 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549806/
2.-
Katzman, Martin & Furtado, Melissa & Anand, Leena. (2014). Acne as a Potential Adverse Effect of Duloxetine. Bulletin of Clinical Psychopharmacology. 24. 408. 10.5455/bcp.20140806014923.
3.-
TEMIZKAN, ABDULGANI & Sevda, Korkmaz & DEMIR, BETL & Atmaca, Murad. (2015). ACNEIFORM ERUPTION DEVELOPING WITH DULOXETINE: A CASE STUDY. Journal of Mood Disorders. 1. 10.5455/jmood.20150831114230.
4.-
Moussavian H. Improvement of acne in depressed patients treated with paroxetine. J Am Acad Child Adolesc Psychiatry. 2001 May;40(5):505-6. doi: 10.1097/00004583-200105000-00007. PMID: 11349692. https://pubmed.ncbi.nlm.nih.gov/11349692/
5.-
Gupta MA, Guptat AK. The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol. 2001 Nov;15(6):512-8. doi: 10.1046/j.1468-3083.2001.00278.x. PMID: 11843209. https://pubmed.ncbi.nlm.nih.gov/11843209/
Find a supportive therapist who can help with Depression.
Discover the convenience of BetterHelp, an online therapy platform connecting you with licensed and accredited therapists specialized in addressing issues such as depression, anxiety, relationships, and more. Complete the assessment and find your ideal therapist within just 48 hours.
AskYourPharm is user-supported. We may earn a commission if you sign up for BetterHelp’s services after clicking through from this site
